Imidazo[4,5-b]pyridine Derivatives As Inhibitors of Aurora Kinases: Lead Optimization Studies toward the Identification of an Orally Bioavailable Preclinical Development Candidate-Reference-Cited by-同舟云学术

Imidazo[4,5-b]pyridine Derivatives As Inhibitors of Aurora Kinases: Lead Optimization Studies toward the Identification of an Orally Bioavailable Preclinical Development Candidate

Published:2010-06-21 Issue:14 Volume:53 Page:5213-5228
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Bavetsias Vassilios¹,Large Jonathan M.¹,Sun Chongbo¹,Bouloc Nathalie¹,Kosmopoulou Magda²,Matteucci Mizio¹,Wilsher Nicola E.¹,Martins Vanessa¹,Reynisson Jóhannes¹,Atrash Butrus¹,Faisal Amir¹,Urban Frederique¹,Valenti Melanie¹,de Haven Brandon Alexis¹,Box Gary¹,Raynaud Florence I.¹,Workman Paul¹,Eccles Suzanne A.¹,Bayliss Richard²,Blagg Julian¹,Linardopoulos Spiros¹³,McDonald Edward¹

Affiliation:

1. Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, United Kingdom

2. Section of Structural Biology, The Institute of Cancer Research, Chester Beatty Laboratories, 237 Fulham Road, London, SW3 6JB, United Kingdom

3. The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, United Kingdom

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm100262j

Reference41 articles.

1. The cellular geography of Aurora kinases